Protara Therapeutics, Inc. Common Stock (TARA) Stock Price

TARAStock
$3.97+24.44%52W
Market Cap$234.61M
P/E
PEG Ratio
Div yield
Beta1.46

TARA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-53.23%
Price vs S&P 500 (4W)-4.83%
VGM Score36.49

TARA Earnings Surprise History

Q2 25-0.35est. -0.41
Q3 25-0.31est. -0.39
Q4 25-0.38est. -0.31
Q1 26-0.31est. -0.37
Q2 26-0.36est. -0.31

TARA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
TARAProtara Therapeutics, Inc. Common Stock
D$3.97
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About Protara Therapeutics, Inc. Common Stock

Protara Therapeutics develops transformative therapies for cancer and rare diseases with limited treatment options. The pipeline includes TARA-002 for lymphatic malformations and intravenous choline chloride for intestinal failure-associated liver disease (IFALD). The company focuses on underserved patient populations with significant unmet medical needs.